Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.11.66 - [histone H3]-trimethyl-L-lysine9 demethylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
Adenocarcinoma of Lung
Histone demethylase KDM5A enhances cell proliferation, induces EMT in lung adenocarcinoma cells, and have a strong causal association with paclitaxel resistance.
KDM3A promotes inhibitory cytokines secretion by participating in TLR4 regulation of Foxp3 transcription in lung adenocarcinoma cells.
LSD1 inhibition attenuates tumor growth by disrupting PLK1 mitotic pathway.
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
Alzheimer Disease
The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration.
Anemia, Sickle Cell
RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases ?-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.
Aortic Aneurysm, Abdominal
Inhibition of macrophage histone demethylase JMJD3 protects against abdominal aortic aneurysms.
Arsenic Poisoning
Histone demethylase JHDM2A regulates H3K9 dimethylation in response to arsenic-induced DNA damage and repair in normal human liver cells.
Arthritis, Rheumatoid
Cystathionine-?-lyase ameliorates the histone demethylase JMJD3-mediated autoimmune response in rheumatoid arthritis.
Histone demethylase JMJD3 regulates fibroblast-like synoviocyte-mediated proliferation and joint destruction in rheumatoid arthritis.
Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells.
Asthma
IL-13 Augments Histone Demethylase JMJD2B/KDM4B Expression Levels, Activity, and Nuclear Translocation in Airway Fibroblasts in Asthma.
Azoospermia
Expression ratio of histone demethylase KDM3A to protamine-1 mRNA is predictive of successful testicular sperm extraction in men with obstructive and non-obstructive azoospermia.
Hsa-miR-27a-3p overexpression in men with nonobstructive azoospermia: A case-control study.
Spermatozoa retrieval in azoospermia and expression profile of JMJD1A, TNP2, and PRM2 in a subset of the Karachi population.
Blast Crisis
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Bone Neoplasms
Lysine-specific demethylase 1 in breast cancer cells contributes to the production of endogenous formaldehyde in the metastatic bone cancer pain model of rats.
Brain Ischemia
Distribution of lysine-specific demethylase 1 in the brain of rat and its response in transient global cerebral ischemia.
Brain Neoplasms
The Malignant Brain Tumor (MBT) Domain Protein SFMBT1 Is an Integral Histone Reader Subunit of the LSD1 Demethylase Complex for Chromatin Association and Epithelial-to-mesenchymal Transition.
Breast Neoplasms
A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer.
ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.
An Aza-Cope Reactivity-Based Fluorescent Probe for Imaging Formaldehyde in Living Cells.
Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer.
Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability.
Comparison of the expression levels of lysine-specific demethylase 1 and survival outcomes between triple-negative and non-triple-negative breast cancer.
Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase.
Corrigendum: The Jumonji Domain-Containing Histone Demethylase Homolog 1D/lysine Demethylase 7A (JHDM1D/KDM7A) Is an Epigenetic Activator of RHOJ Transcription in Breast Cancer Cells.
Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor ? (ER?) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
Effects of siRNA-mediated knockdown of jumonji domain containing 2A on proliferation, migration and invasion of the human breast cancer cell line MCF-7.
ERR? protein is stabilized by LSD1 in a demethylation-independent manner.
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.
Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development.
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.
Histone demethylase JMJD2C: epigenetic regulators in tumors.
Histone demethylase JMJD5 is essential for embryonic development.
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Histone demethylase KDM6B inhibits breast cancer metastasis by regulating Wnt/?-catenin signaling.
Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer.
Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis.
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM3A regulates Slug expression to promote the invasion of MCF7 breast cancer cells in hypoxia.
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression.
Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
Lysine demethylase KDM3A regulates nanophotonic hyperthermia resistance generated by 2D silicene in breast cancer.
Lysine-specific demethylase 1 in breast cancer cells contributes to the production of endogenous formaldehyde in the metastatic bone cancer pain model of rats.
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.
MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ER?-positive breast cancer.
Oncogenic features of the JMJD2A histone demethylase in breast cancer.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells.
Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients.
The Dual Function of KDM5C in Both Gene Transcriptional Activation and Repression Promotes Breast Cancer Cell Growth and Tumorigenesis.
The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.
The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer.
The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia.
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.
The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells.
The Histone Demethylase LSD1/?DM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program.
The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L.
The Jumonji Domain-Containing Histone Demethylase Homolog 1D/lysine Demethylase 7A (JHDM1D/KDM7A) Is an Epigenetic Activator of RHOJ Transcription in Breast Cancer Cells.
The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes.
The R251Q mutation of LSD1 promotes invasion and migration of luminal breast cancer cells.
The zinc-finger transcriptional factor Slug transcriptionally downregulates ER? by recruiting lysine-specific demethylase 1 in human breast cancer.
UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells.
UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor.
[Knockdown of lysine-specific demethylase 3A (KDM3A) inhibits the invasion and migration of MDA-MB-231 breast cancer cells and arrests the cell cycle in the G0/G1 phase].
Carcinogenesis
A developmental genetic analysis of the lysine demethylase KDM2 mutations in Drosophila melanogaster.
Acetylation of PHF5A Modulates Stress Responses and Colorectal Carcinogenesis through Alternative Splicing-Mediated Upregulation of KDM3A.
Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells.
Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma.
E2F1-induced ferritin heavy chain 1 pseudogene 3 (FTH1P3) accelerates non-small cell lung cancer gefitinib resistance.
Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer.
Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B.
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.
High-Throughput TR-FRET Assays for Identifying Inhibitors of LSD1 and JMJD2C Histone Lysine Demethylases.
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone lysine demethylases in Drosophila melanogaster.
Human Hairless Protein Roles in Skin/Hair and Emerging Connections to Brain and Other Cancers.
In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis.
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases.
JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells.
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene.
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
KDM4A regulates myogenesis by demethylating H3K9me3 of myogenic regulatory factors.
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer.
LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
Lysine-specific demethylase 1 (LSD1/KDM1A) contributes to colorectal tumorigenesis via activation of the Wnt/?-catenin pathway by down-regulating Dickkopf-1 (DKK1).
Lysine-specific demethylase 1 accelerates oncogenesis in p53 heterozygous mice via transcriptional repression of the residual Trp53 allele.
Lysine-specific demethylase 1 promotes tumorigenesis and predicts prognosis in gallbladder cancer.
MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer.
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
Nuclear GSK3? promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22.
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer.
Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma.
Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles.
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
The Dual Function of KDM5C in Both Gene Transcriptional Activation and Repression Promotes Breast Cancer Cell Growth and Tumorigenesis.
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b).
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1.
ZNFX1 anti-sense RNA 1 promotes the tumorigenesis of prostate cancer by regulating c-Myc expression via a regulatory network of competing endogenous RNAs.
Carcinoma
Contingencies of UTX/KDM6A Action in Urothelial Carcinoma.
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.
Effect of Hypoxia on Proliferation and the Expression of the Genes HIF-1? and JMJD1A in Head and Neck Squamous Cell Carcinoma Cell Lines.
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Genome-wide ChIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells.
High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Histone demethylase JMJD2C: epigenetic regulators in tumors.
Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells.
Identification and characterization of JMJD2 family genes in silico.
JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma.
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Lysine demethylase 3a in craniofacial and neural development during Xenopus embryogenesis.
microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1.
Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C.
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription.
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma.
Regulation of the Histone Demethylase JMJD1A by HIF-1{alpha} Enhances Hypoxic Gene Expression and Tumor Growth.
The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development.
The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma.
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
The Prognostic Significance of Histone Demethylase UTX in Esophageal Squamous Cell Carcinoma.
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Carcinoma, Embryonal
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.
The histone demethylase Kdm3a is essential to progression through differentiation.
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
Carcinoma, Hepatocellular
Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Hepatitis B virus X protein induces the histone H3 lysine 9 trimethylation on the promoter of p16 gene in hepatocarcinogenesis.
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis.
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.
Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection.
The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia.
[Effect of Basil Polysaccharide on Histone H3K9me2 Methylation and Expression of G9a and JMJD1A in Hepatoma Cells Under Hypoxic Conditions].
Carcinoma, Non-Small-Cell Lung
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer.
KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.
Retraction note to: KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.
ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression.
Carcinoma, Renal Cell
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
KDM3A is not associated with metastasis and prognosis of breast cancer.
The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma.
Carcinoma, Squamous Cell
Effect of Hypoxia on Proliferation and the Expression of the Genes HIF-1? and JMJD1A in Head and Neck Squamous Cell Carcinoma Cell Lines.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Cardiomegaly
Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis.
JMJD1A Represses the Development of Cardiomyocyte Hypertrophy by Regulating the Expression of Catalase.
The histone demethylase PHF8 represses cardiac hypertrophy upon pressure overload.
Cardiomyopathies
Epigenetic reprogramming to prevent genetic cardiomyopathy.
Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression.
Mutations of histone demethylase genes encoded by X and Y chromosomes, Kdm5c and Kdm5d, lead to noncompaction cardiomyopathy in mice.
Targeting the histone demethylase LSD1 prevents cardiomyopathy in a mouse model of laminopathy.
Cardiomyopathy, Hypertrophic
JMJD1A Represses the Development of Cardiomyocyte Hypertrophy by Regulating the Expression of Catalase.
Cardiovascular Diseases
KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway.
CHARGE Syndrome
Knockdown of fbxl10/kdm2bb rescues chd7 morphant phenotype in a zebrafish model of CHARGE syndrome.
Chickenpox
Transcriptional coactivator HCF-1 couples the histone chaperone Asf1b to HSV-1 DNA replication components.
Chondrosarcoma
Antiproliferative effect of the histone demethylase inhibitor GSK-J4 in chondrosarcomas.
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells.
Colitis
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
The demethylase inhibitor GSK-J4 limits inflammatory colitis by promoting de novo synthesis of retinoic acid in dendritic cells.
Colitis-Associated Neoplasms
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Colonic Neoplasms
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
Acetylation of PHF5A Modulates Stress Responses and Colorectal Carcinogenesis through Alternative Splicing-Mediated Upregulation of KDM3A.
Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells.
Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer.
Epigenetic regulation of E-cadherin expression by the histone demethylase UTX in colon cancer cells.
Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.
Histone Demethylases in Colon Cancer.
Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells.
KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.
KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells.
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states.
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
[The influence and mechanisms of lysine-specific demethylase 1 (LSD1) on invasion and metastasis of colon cancer cells].
Colorectal Neoplasms
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.
Clinical Significance of Histone Demethylase NO66 in Invasive Colorectal Cancer.
Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer.
Correction to: Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B.
HIF-1?-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism.
Histone Demethylase Gene PHF2 Is Mutated in Gastric and Colorectal Cancers.
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Histone demethylase PHF8 accelerates the progression of colorectal cancer and can be regulated by miR-488 in vitro.
IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases.
JIB-04, A Small Molecule Histone Demethylase Inhibitor, Selectively Targets Colorectal Cancer Stem Cells by Inhibiting the Wnt/?-Catenin Signaling Pathway.
JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing ?-catenin signaling pathway.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in PIK3CA-Mutant Colorectal Cancer.
Opposite Roles of the JMJD1A Interaction Partners MDFI and MDFIC in Colorectal Cancer.
Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer.
Congenital Abnormalities
Lysine demethylase 3a in craniofacial and neural development during Xenopus embryogenesis.
Coronary Artery Disease
Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats.
Dehydration
Arabidopsis histone H3K4 demethylase JMJ17 functions in dehydration stress response.
Diabetes Mellitus, Type 2
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Histone demethylases regulate adipocyte thermogenesis.
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Diabetic Nephropathies
Histone demethylase UTX is a therapeutic target for diabetic kidney disease.
Diabetic Retinopathy
Epigenetic modifications and diabetic retinopathy.
Diffuse Intrinsic Pontine Glioma
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
Encephalomyelitis
A silent exonic SNP in kdm3a affects nucleic acids structure but does not regulate experimental autoimmune encephalomyelitis.
X-tra X: An escape to autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
A silent exonic SNP in kdm3a affects nucleic acids structure but does not regulate experimental autoimmune encephalomyelitis.
X-tra X: An escape to autoimmunity.
Endodermal Sinus Tumor
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
Endometrial Neoplasms
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Endometriosis
Overexpression of lysine-specific demethylase 1 in ovarian endometriomas and its inhibition reduces cellular proliferation, cell cycle progression, and invasiveness.
Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis.
Epilepsy
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Esophageal Neoplasms
MicroRNA let-7i Inhibits Histone Lysine Demethylase KDM5B to Halt Esophageal Cancer Progression.
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer.
Esophageal Squamous Cell Carcinoma
Genome-wide ChIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells.
High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells.
Identification and characterization of JMJD2 family genes in silico.
JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma.
Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma.
The Prognostic Significance of Histone Demethylase UTX in Esophageal Squamous Cell Carcinoma.
Familial Primary Pulmonary Hypertension
Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function.
Fanconi Anemia
Fanconi Anemia FANCM/FNCM-1 and FANCD2/FCD-2 Are Required for Maintaining Histone Methylation Levels and Interact with the Histone Demethylase LSD1/SPR-5 in
Gallbladder Neoplasms
Lysine-specific demethylase 1 promotes tumorigenesis and predicts prognosis in gallbladder cancer.
Gastritis
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Gastrointestinal Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Gastrointestinal Stromal Tumors
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Genetic Diseases, Inborn
LSD1/KDM1A mutations associated to a newly described form of intellectual disability impair demethylase activity and binding to transcription factors.
Glioblastoma
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation.
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1?-dependent pathway.
Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3.
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Glioma
Downregulation of KDM4A Suppresses the Survival of Glioma Cells by Promoting Autophagy.
Hairless regulates p53 target genes to exert tumor suppressive functions in glioblastoma.
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Histone demethylase KDM6B regulates 1,25-dihydroxyvitamin D3-induced senescence in glioma cells.
KDM1 is a novel therapeutic target for the treatment of gliomas.
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling.
The Histone Demethylase NO66 Induces Glioma Cell Proliferation.
The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells.
Glomerulonephritis
The histone demethylase LSD1 promotes renal inflammation by mediating TLR4 signaling in hepatitis B virus-associated glomerulonephritis.
Hematologic Diseases
JHDM1D and HDAC1-3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Hematologic Neoplasms
KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RAR?.
Hepatitis B
The histone demethylase LSD1 promotes renal inflammation by mediating TLR4 signaling in hepatitis B virus-associated glomerulonephritis.
Herpes Simplex
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.
Transcriptional coactivator HCF-1 couples the histone chaperone Asf1b to HSV-1 DNA replication components.
Herpes Zoster
Transcriptional coactivator HCF-1 couples the histone chaperone Asf1b to HSV-1 DNA replication components.
Hirschsprung Disease
KDM5B promotes cell migration by regulating the noncanonical Wnt/PCP pathway in Hirschsprung's disease.
Huntington Disease
Systematic genetic interaction studies identify histone demethylase Utx as potential target for ameliorating Huntington's disease.
Hyperalgesia
Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis.
Hypercholesterolemia
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Hyperglycemia
Epigenetic modifications of Nrf2-mediated glutamate-cysteine ligase: implications for the development of diabetic retinopathy and the metabolic memory phenomenon associated with its continued progression.
Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail.
Hyperinsulinism
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Hyperlipidemias
Histone Demethylase JHDM2A Is Involved in Male Infertility and Obesity.
Role of Jhdm2a in regulating metabolic gene expression and obesity resistance.
Hypersensitivity
Arabidopsis histone H3K4 demethylase JMJ17 functions in dehydration stress response.
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Hypertension
Histone demethylase LSD1 and biological sex: impact on blood pressure and aldosterone production.
Histone Demethylase LSD1 Deficiency during High Salt Diet is Associated with Enhanced Vascular Contraction, Altered NO-cGMP Relaxation Pathway, and Hypertension.
Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function.
Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension.
Hypertension, Pulmonary
Histone demethylase JARID1B regulates proliferation and migration of pulmonary arterial smooth muscle cells in mice with chronic hypoxia-induced pulmonary hypertension via nuclear factor-kappa B (NFkB).
Hypertriglyceridemia
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Infections
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B.
Epigenetic factor siRNA screen during primary KSHV infection identifies novel host restriction factors for the lytic cycle of KSHV.
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
KDM2B Overexpression Facilitates Lytic De Novo KSHV Infection by Inducing AP-1 Activity Through Interaction with the SCF E3 Ubiquitin Ligase Complex.
Role of Serum Amyloid A, Granulocyte-Macrophage Colony-Stimulating Factor, and Bone Marrow Granulocyte-Monocyte Precursor Expansion in Segmented Filamentous Bacterium-Mediated Protection from Entamoeba histolytica.
Infertility
Identification of Two Novel Mutations in KDM3A Regulatory Gene in Iranian Infertile Males
Jmjd1a demethylase-regulated histone modification is essential for cAMP-response element modulator-regulated gene expression and spermatogenesis.
Spermatozoa retrieval in azoospermia and expression profile of JMJD1A, TNP2, and PRM2 in a subset of the Karachi population.
Infertility, Female
The histone H3K9 demethylase Kdm3b is required for somatic growth and female reproductive function.
Infertility, Male
Association between polymorphisms of exon 12 and exon 24 of JHDM2A gene and male infertility.
Evaluation of mRNA Contents of YBX2 and JHDM2A Genes on Testicular Tissues of Azoospermic Men with Different Classes of Spermatogenesis.
Histone Demethylase JHDM2A Is Involved in Male Infertility and Obesity.
Identification of Two Novel Mutations in KDM3A Regulatory Gene in Iranian Infertile Males
Spermatozoa retrieval in azoospermia and expression profile of JMJD1A, TNP2, and PRM2 in a subset of the Karachi population.
Inflammatory Bowel Diseases
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Influenza, Human
Correction: Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.
Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.
Insulin Resistance
Metabolic and energetic benefits of microRNA-22 inhibition.
Intellectual Disability
A Drosophila Model of Intellectual Disability Caused by Mutations in the Histone Demethylase KDM5.
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Crystal structure of the PHF8 Jumonji domain, an Nepsilon-methyl lysine demethylase.
De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism.
Epigenetic regulation in human brain-focus on histone lysine methylation.
Molecular and cellular events linking variants in the histone demethylase KDM5C to the intellectual disability disorder Claes-Jensen syndrome.
Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway.
Intervertebral Disc Degeneration
microRNA-155-3p attenuates intervertebral disc degeneration via inhibition of KDM3A and HIF1?.
Ischemic Stroke
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Kidney Neoplasms
Ascorbate antagonizes nickel ion to regulate JMJD1A expression in kidney cancer cells.
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity.
In vitro evidence of NLRP3 inflammasome regulation by histone demethylase LSD2 in renal cancer: a pilot study.
The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma.
The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.
Laminopathies
Targeting the histone demethylase LSD1 prevents cardiomyopathy in a mouse model of laminopathy.
Lentivirus Infections
[Knockdown of lysine-specific demethylase 3A (KDM3A) inhibits the invasion and migration of MDA-MB-231 breast cancer cells and arrests the cell cycle in the G0/G1 phase].
Leukemia
Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia.
KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RAR?.
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Modulators of histone demethylase JMJD1C selectively target leukemic stem cells.
Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia.
USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.
Utx loss causes myeloid transformation.
[Expression of histone demethylase lysine specific demethylase 1 in acute leukemia and its clinical significance].
[Research Advances in Lysine-specific Demethylase 6A and Its Application in Treating Leukemia].
Leukemia, Erythroblastic, Acute
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Leukemia, Lymphocytic, Chronic, B-Cell
Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Leukemia, Myeloid
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.
Leukemia, Myeloid, Acute
A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer.
Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
ORY-1001: Overcoming the Differentiation Block in AML.
Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Leukemia, Myelomonocytic, Chronic
Utx loss causes myeloid transformation.
Leukemia, Promyelocytic, Acute
The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia.
Leukemia, T-Cell
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Liver Cirrhosis
Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor ?
Liver Neoplasms
Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of ?-catenin signaling.
Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of ?-catenin signaling.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Lung Neoplasms
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Epigenetic regulation of lung cancer cell proliferation and migration by the chromatin remodeling protein BRG1.
Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis.
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/?-catenin signaling pathway.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
KDM5C Expedites Lung Cancer Growth and Metastasis Through Epigenetic Regulation of MicroRNA-133a.
Long noncoding RNA actin filament-associated protein 1 antisense RNA 1 promotes malignant phenotype through binding with lysine-specific demethylase 1 and repressing HMG box-containing protein 1 in non-small-cell lung cancer.
MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1? axis.
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-?2 transcription.
Lupus Erythematosus, Systemic
Histone demethylase JMJD3 regulates CD11a expression through changes in histone H3K27 tri-methylation levels in CD4+ T cells of patients with systemic lupus erythematosus.
JHDM1D and HDAC1-3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Lymphatic Metastasis
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer.
KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
Lymphoma
Cooperative epigenetic modulation by cancer amplicon genes.
Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of ODZ2, JMJD2C, and CNN3.
Lymphoma, B-Cell
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Lymphoma, B-Cell, Marginal Zone
Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of ODZ2, JMJD2C, and CNN3.
Lymphoma, Non-Hodgkin
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Mastitis
Lysine-specific demethylase 1 (LSD1) serves as an potential epigenetic determinant to regulate inflammatory responses in mastitis.
Medulloblastoma
Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
Melanoma
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
Memory Disorders
Deletion of JMJD2B in neurons leads to defective spine maturation, hyperactive behavior and memory deficits in mouse.
Environmental enrichment reverses histone methylation changes in the aged hippocampus and restores age-related memory deficits.
Mental Retardation, X-Linked
A distinctive gene expression fingerprint in mentally retarded male patients reflects disease-causing defects in the histone demethylase KDM5C.
A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation.
A PHF8 homolog in C. elegans promotes DNA repair via homologous recombination.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
The histone demethylase PHF8 is essential for cytoskeleton dynamics.
The X-linked mental retardation gene PHF8 is a histone demethylase involved in neuronal differentiation.
Mesothelioma
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
KDM6B histone demethylase is an epigenetic regulator of estrogen receptor ? expression in human pleural mesothelioma.
Mesothelioma, Malignant
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Metabolic Syndrome
Histone demethylases regulate adipocyte thermogenesis.
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Mouth Neoplasms
Resveratrol in Various Pockets: A Review.
The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Multiple Myeloma
Hypoxia-inducible KDM3A addiction in multiple myeloma.
JMJD2C triggers the growth of multiple myeloma cells via activation of ??catenin.
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMJD2B.
Myelodysplastic Syndromes
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Myocardial Infarction
KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway.
Targeting JMJD3 histone demethylase mediates cardiac fibrosis and cardiac function following myocardial infarction.
The histone demethylase JMJD2B regulates endothelial-to-mesenchymal transition.
Nasopharyngeal Carcinoma
Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A.
Neoplasm Metastasis
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.
Bioactivity evaluation of natural product ?-mangostin as a novel xanthone-based lysine-specific demethylase 1 inhibitor to against tumor metastasis.
Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.
Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Histone demethylase KDM6B inhibits breast cancer metastasis by regulating Wnt/?-catenin signaling.
Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/?-catenin signaling pathway.
Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.
Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells.
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
JMJD2B promotes epithelial-mesenchymal transition by cooperating with ?-catenin and enhances gastric cancer metastasis.
JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing ?-catenin signaling pathway.
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer.
KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
KDM5C Expedites Lung Cancer Growth and Metastasis Through Epigenetic Regulation of MicroRNA-133a.
LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support BRAF-Mutant Colorectal Cancer.
LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer.
Lysine-specific demethylase 1 promotes tumorigenesis and predicts prognosis in gallbladder cancer.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Retraction note to: KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1.
The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L.
[The influence and mechanisms of lysine-specific demethylase 1 (LSD1) on invasion and metastasis of colon cancer cells].
Neoplasms
(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators.
4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
A developmental genetic analysis of the lysine demethylase KDM2 mutations in Drosophila melanogaster.
A dual role of dLsd1 in oogenesis: regulating developmental genes and repressing transposons.
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.
A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer.
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
A systematic study of the cellular metabolic regulation of Jhdm1b in tumor cells.
Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.
Advances in Histone Demethylase KDM3A as a Cancer Therapeutic Target.
Advances in histone demethylase KDM4 as cancer therapeutic targets.
Advances in the development of histone lysine demethylase inhibitors.
Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
An Overview of Phenylcyclopropylamine Derivatives: Biochemical and Biological Significance and Recent Developments.
An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma.
An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines.
Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer.
Ascorbate antagonizes nickel ion to regulate JMJD1A expression in kidney cancer cells.
Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Bioactivity evaluation of natural product ?-mangostin as a novel xanthone-based lysine-specific demethylase 1 inhibitor to against tumor metastasis.
Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview.
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer.
Crystal Structure of LSD1 in Complex with 4-[5-(Piperidin-4-ylmethoxy)-2-(p-tolyl)pyridin-3-yl]benzonitrile.
Crystal Structure of the LSD1/CoREST Histone Demethylase Bound to Its Nucleosome Substrate.
Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design.
Cyclic peptide inhibitors of lysine-specific demethylase 1 with improved potency identified by alanine scanning mutagenesis.
Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Demethylation of Di-Methylation of Lysine 4 on Histone 3 Is Inhibited by General Control Nondepressible 5-Induced Acetylation of Lysine-Specific Demethylase 1.
Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells.
Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Design, synthesis and evaluation of ?-turn mimetics as LSD1-selective inhibitors.
Design, synthesis, and biological evaluation of a conjugate of 5-fluorouracil and an LSD1 inhibitor.
Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating ?,?-Disubstituted Amino Acids with ?-Turn-Inducing Structures.
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
Downregulation of KDM4A Suppresses the Survival of Glioma Cells by Promoting Autophagy.
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression.
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets.
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Epstein-Barr Virus Nuclear Antigen 3C Inhibits Expression of COBLL1 and the ADAM28-ADAMDEC1 Locus via Interaction with the Histone Lysine Demethylase KDM2B.
ERR? protein is stabilized by LSD1 in a demethylation-independent manner.
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
Further insights into the SAR of ?-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A.
GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
Gentle, fast and effective crystal soaking by acoustic dispensing.
Getting to the heart of the matter in cancer: Novel approaches to targeting cancer stem cells.
HIF-1?-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism.
High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma.
High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer.
Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1?.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development.
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Histone demethylase JMJD2B-mediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell.
Histone demethylase JMJD2C: epigenetic regulators in tumors.
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression.
Histone demethylase JMJD3 at the intersection of cellular senescence and cancer.
Histone demethylase Jmjd3 modulates osteoblast apoptosis induced by tumor necrosis factor-alpha through directly targeting RASSF5.
Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization.
Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3.
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis.
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy.
Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells.
Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT.
Histone demethylase lysine demethylase 5B in development and cancer.
Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/?-catenin signaling pathway.
Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
Histone H3 binding to the PHD1 domain of histone demethylase KDM5A enables active site remodeling.
Histone lysine demethylases as targets for anticancer therapy.
Histone lysine demethylases in Drosophila melanogaster.
Histone methyltransferase and drug resistance in cancers.
Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer.
Hypoxia induced expression of histone lysine demethylases: implications in oxygen-dependent retinal neovascular diseases.
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
Identification of Deregulated Signaling Pathways in Jurkat Cells in Response to a Novel Acylspermidine Analogue-N4-Erucoyl Spermidine.
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Identification of new Wilms tumour predisposition genes: an exome sequencing study.
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Impairment of Preimplantation Porcine Embryo Development by Histone Demethylase KDM5B Knockdown Through Disturbance of Bivalent H3K4me3-H3K27me3 Modifications.
Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.
Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor associated macrophages.
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives.
Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells.
Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1?-dependent pathway.
Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Integrated genomic analyses identify KDM1A's role in cell proliferation via modulating E2F signaling activity and associate with poor clinical outcome in oral cancer.
Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma.
JARID1 Histone Demethylases: Emerging Targets in Cancer.
JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.
JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells.
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma.
JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells.
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
JMJD1B, a novel player in histone H3 and H4 processing to ensure genome stability.
JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells.
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy.
Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene.
JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing ?-catenin signaling pathway.
JMJD2C triggers the growth of multiple myeloma cells via activation of ??catenin.
Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM3A regulates Slug expression to promote the invasion of MCF7 breast cancer cells in hypoxia.
KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.
KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RAR?.
KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.
KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors.
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
KDM4B Overexpression Promotes the Growth, Migration, and Invasion of Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Activating STAT3 Pathway.
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism.
KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis.
KDM6B promotes ovarian cancer cell migration and invasion by induced transforming growth factor-?1 expression.
Kinetic analysis of iron-dependent histone demethylases: ?-ketoglutarate substrate inhibition and potential relevance to the regulation of histone demethylation in cancer cells.
Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer.
Long non-coding RNA KIKAT/LINC01061 as a novel epigenetic regulator that relocates KDM4A on chromatin and modulates viral reactivation.
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Loss of lysine-specific demethylase 1 nonautonomously causes stem cell tumors in the Drosophila ovary.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Low Molecular Weight Amidoximes that Act as Potent Inhibitors of Lysine-Specific Demethylase 1.
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.
LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support BRAF-Mutant Colorectal Cancer.
LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter.
LSD1 demethylates HIF1? to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis.
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.
LSD1 inhibition attenuates tumor growth by disrupting PLK1 mitotic pathway.
LSD1 Inhibition Promotes Epithelial Differentiation through Derepression of Fate-Determining Transcription Factors.
LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer.
LSD1 modulates the non-canonical integrin ?3 signaling pathway in non-small cell lung carcinoma cells.
LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression.
LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion.
LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer.
LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies.
Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms.
Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Potential Treatment for Different Types of Cancers.
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1? and microRNA-146a.
Lysine-specific demethylase 1 inhibition enhances autophagy and attenuates early-stage post-spinal cord injury apoptosis.
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells.
Lysine-specific demethylase-1 regulates fibroblast activation in pulmonary fibrosis via TGF-?1/Smad3 pathway.
Macrocyclic Peptides Uncover a Novel Binding Mode for Reversible Inhibitors of LSD1.
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.
Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.
microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1.
microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1?/HES1 signaling axis.
MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation.
miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ER?-positive breast cancer.
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.
MOF Acetylates the Histone Demethylase LSD1 to Suppress Epithelial-to-Mesenchymal Transition.
Molecular cloning, tissue expression, and analysis with genome DNA methylation of porcine LSD1 gene.
Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells.
Nitroreductase-Mediated Release of Inhibitors of Lysine-Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells.
Novel germline variant in the histone demethylase and transcription regulator KDM4C induces a multi-cancer phenotype.
Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.
Nuclear import of human histone lysine-specific demethylase LSD1.
Oncogenic KRAS sensitizes lung adenocarcinoma to GSK-J4-induced metabolic and oxidative stress.
Opposite Roles of the JMJD1A Interaction Partners MDFI and MDFIC in Colorectal Cancer.
ORY-1001: Overcoming the Differentiation Block in AML.
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer.
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma.
Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
p53-targeted LSD1 functions in repression of chromatin structure and transcription in vivo.
Pathophysiological Response to Hypoxia - From the Molecular Mechanisms of Malady to Drug Discovery:Epigenetic Regulation of the Hypoxic Response via Hypoxia-Inducible Factor and Histone Modifying Enzymes.
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer.
PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma.
Polyamine-based small molecule epigenetic modulators.
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Prognostic role of LSD1 in various cancers: evidence from a meta-analysis.
Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
Prominent role of histone lysine demethylases in cancer epigenetics and therapy.
Recognition of Histone H3 Methylation States by the PHD1 Domain of Histone Demethylase KDM5A.
Regional tumour glutamine supply affects chromatin and cell identity.
Regulation of the Histone Demethylase JMJD1A by HIF-1{alpha} Enhances Hypoxic Gene Expression and Tumor Growth.
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells.
Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth.
Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
Simultaneous Inhibition of LSD1 and TGF? Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Stable H3 peptide was delivered by gold nanorods to inhibit LSD1 activation and induce human mesenchymal stem cells differentiation.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Structure-Based Design of a New Scaffold for Cell-Penetrating Peptidic Inhibitors of the Histone Demethylase PHF8.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells.
Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.
Targeting histone demethylase KDM5B for cancer treatment.
Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy.
Targeting of KDM5A by miR-421 in Human Ovarian Cancer Suppresses the Progression of Ovarian Cancer Cells.
Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.
Targeting the USP1 dependent KDM4A protein stability as a potential prostate cancer therapy.
The critical role of histone lysine demethylase KDM2B in cancer.
The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development.
The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma.
The histone demethylase Jarid1b is required for hematopoietic stem cell self-renewal.
The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia.
The histone demethylase JMJD2A/KDM4A links ribosomal RNA transcription to nutrients and growth factors availability.
The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
The histone demethylase Kdm3a is required for normal epithelial proliferation, ductal elongation and tumor growth in the mouse mammary gland.
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
The Histone Demethylase LSD1 Inhibits Tumor Cell Immunogenicity.
The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells.
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
The histone demethylase RBP2 is over-expressed in gastric cancer and its inhibition triggers senescence of cancer cells.
The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.
The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1.
The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L.
The histone LSD1 demethylase in stemness and cancer transcription programs.
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
The KDM5 family of histone demethylases as targets in oncology drug discovery.
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy.
The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.
The pseudogene derived from long non-coding RNA DUXAP10 promotes colorectal cancer cell growth through epigenetically silencing of p21 and PTEN.
The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer.
The Pseudogene DUXAP8 Promotes Non-small-cell Lung Cancer Cell Proliferation and Invasion by Epigenetically Silencing EGR1 and RHOB.
The retinoblastoma binding protein RBP2 is an H3K4 demethylase.
The role of the histone demethylase KDM4A in cancer.
The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) In Cancers: Current Progress and Future Perspectives.
The roles of LSD1-mediated epigenetic modifications in maintaining the pluripotency of bladder cancer stem cells.
The Siah2-HIF-FoxA2 axis in prostate cancer - new markers and therapeutic opportunities.
The tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone demethylase.
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Tudor domain of histone demethylase KDM4B is a reader of H4K20me3.
Tumor suppression by the histone demethylase UTX.
Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Unravelling KDM4 histone demethylase inhibitors for cancer therapy.
Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT.
Upregulation of PSMD10 caused by the JMJD2A histone demethylase.
UTX - moonlighting in the cytoplasm?
Utx loss causes myeloid transformation.
[Novel epigenetic therapies for multiple myeloma].
Neoplasms, Germ Cell and Embryonal
Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer.
Neoplasms, Plasma Cell
[Novel epigenetic therapies for multiple myeloma].
Nervous System Diseases
Tranylcypromine reduces herpes simplex virus 1 infection in mice.
Neuralgia
MiR-216a-5p alleviates chronic constriction injury-induced neuropathic pain in rats by targeting KDM3A and inactivating Wnt/?-catenin signaling pathway.
The histone demethylase JMJD2A regulates the expression of BDNF and mediates neuropathic pain in mice.
Neuroblastoma
Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation.
Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives.
Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.
MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells.
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1.
The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
Neurodegenerative Diseases
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Targeting Histone Demethylase LSD1/KDM1a in Neurodegenerative Diseases.
Neurofibrosarcoma
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Neuroinflammatory Diseases
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
RNA sequencing reveals resistance of TLR4 ligand-activated microglial cells to inflammation mediated by the selective jumonji H3K27 demethylase inhibitor.
Non-alcoholic Fatty Liver Disease
Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Obesity
Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Histone Demethylase JHDM2A Is Involved in Male Infertility and Obesity.
Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats.
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Regulation of adipogenesis by nuclear receptor PPAR? is modulated by the histone demethylase JMJD2C.
Role of Jhdm2a in regulating metabolic gene expression and obesity resistance.
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Oligospermia
Jmjd1a demethylase-regulated histone modification is essential for cAMP-response element modulator-regulated gene expression and spermatogenesis.
Oropharyngeal Neoplasms
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
Osteoarthritis, Knee
Synovial Mesenchymal Stem Cell-Derived EV-Packaged miR-31 Downregulates Histone Demethylase KDM2A to Prevent Knee Osteoarthritis.
Osteosarcoma
Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.
Correction to: microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1?/HES1 signaling axis.
Histone Demethylase JARID1B is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression Via Demethylation of H3K27me3.
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Histone demethylase JMJD2C: epigenetic regulators in tumors.
Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor.
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1?/HES1 signaling axis.
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Ovarian Neoplasms
Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.
Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines.
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone Demethylase KDM4C Is Required for Ovarian Cancer Stem Cell Maintenance.
Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells.
LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion.
Lysine-Specific Demethylase 1 (LSD1) Inhibitor S2101 Induces Autophagy via the AKT/mTOR Pathway in SKOV3 Ovarian Cancer Cells.
Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells.
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
Pancreatic Neoplasms
circZMYM2 Competed Endogenously with miR-335-5p to Regulate JMJD2C in Pancreatic Cancer.
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Incorporating multiple sets of eQTL weights into gene-by-environment interaction analysis identifies novel susceptibility loci for pancreatic cancer.
KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP?
PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells.
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.
Parkinson Disease
Therapeutic effect of a histone demethylase inhibitor in Parkinson's disease.
Persistent Infection
Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection.
Polycythemia Vera
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
Pre-Eclampsia
Compromised JMJD6 histone demethylase activity impacts on VHL gene repression in preeclampsia.
Overexpression of let-7d explains down-regulated KDM3A and ENO2 in the pathogenesis of preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia.
The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway.
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Prostatic Neoplasms
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Downregulation of lysine-specific demethylase 1 enhances the sensitivity of hormone-sensitive prostate cancer cells to androgen deprivation therapy.
Epigenetic therapy in urologic cancers: an update on clinical trials.
EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer.
Genetic alterations and changes in expression of histone demethylases in prostate cancer.
Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.
Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells.
Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer.
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.
Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
LSD1 controls metastasis of androgen-independent prostate cancer cells through PXN and LPAR6.
MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy.
NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.
Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer.
Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Role of UTX Histone Demethylase in Regulation of MGMT, TRA2A, U2AF1, and RPS6KA2 Genes in Prostate Cancer Cell Lines.
Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Sumoylation of transcription factor ETV1 modulates its oncogenic potential in prostate cancer.
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer.
Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
The histone demethylase PHF8 promotes prostate cancer cell growth by activating the oncomiR miR-125b.
The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.
Upregulation of PSMD10 caused by the JMJD2A histone demethylase.
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.
ZNFX1 anti-sense RNA 1 promotes the tumorigenesis of prostate cancer by regulating c-Myc expression via a regulatory network of competing endogenous RNAs.
Respiratory Insufficiency
The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3.
Retinal Diseases
Hypoxia induced expression of histone lysine demethylases: implications in oxygen-dependent retinal neovascular diseases.
Retinoblastoma
Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp.
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
Histone demethylase retinoblastoma binding protein 2 regulates the expression of ?-smooth muscle actin and vimentin in cirrhotic livers.
Inhibition of osteogenic differentiation of human adipose-derived stromal cells by retinoblastoma binding protein 2 repression of RUNX2-activated transcription.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.
Targeting of KDM5A by miR-421 in Human Ovarian Cancer Suppresses the Progression of Ovarian Cancer Cells.
The retinoblastoma binding protein RBP2 is an H3K4 demethylase.
Rhabdomyosarcoma
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells.
Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A.
Sarcoma
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A.
Sarcoma, Ewing
Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma.
KDM3A is not associated with metastasis and prognosis of breast cancer.
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth.
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.
Sarcoma, Synovial
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
Scleroderma, Systemic
The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis.
Seminoma
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
Sepsis
GSKJ4 Protects Mice Against Early Sepsis via Reducing Proinflammatory Factors and Up-Regulating MiR-146a.
Shock, Septic
Endogenous hydrogen sulfide regulates histone demethylase JMJD3-mediated inflammatory response in LPS-stimulated macrophages and in a mouse model of LPS-induced septic shock.
Small Cell Lung Carcinoma
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Solitary Fibrous Tumors
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Spondylitis, Ankylosing
The histone demethylase JARID1A is associated with susceptibility to ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Effect of Hypoxia on Proliferation and the Expression of the Genes HIF-1? and JMJD1A in Head and Neck Squamous Cell Carcinoma Cell Lines.
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.
JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma.
microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1.
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Starvation
A CxxC Domain That Binds to Unmethylated CpG Is Required for KDM2A to Control rDNA Transcription.
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.
Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor associated macrophages.
JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy.
Stomach Neoplasms
Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer.
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer.
Expression pattern of histone lysine-specific demethylase 6B in gastric cancer.
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Histone demethylase JMJD2B-mediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell.
Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3.
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
JMJD2B promotes epithelial-mesenchymal transition by cooperating with ?-catenin and enhances gastric cancer metastasis.
KDM3A interacted with p53K372me1 and regulated p53 binding to PUMA in gastric cancer.
Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness.
Lysine-specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC-803.
MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer.
shRNA-interfering LSD1 inhibits proliferation and invasion of gastric cancer cells via VEGF-C/PI3K/AKT signaling pathway.
Targeting the histone demethylase PHF8-mediated PKC?-Src-PTEN axis in HER2-negative gastric cancer.
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
The histone demethylase RBP2 is over-expressed in gastric cancer and its inhibition triggers senescence of cancer cells.
Teratocarcinoma
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Teratoma
Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells.
Teratozoospermia
Kdm3a lysine demethylase is an Hsp90 client required for cytoskeletal rearrangements during spermatogenesis.
Testicular Neoplasms
PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma.
Thyroid Cancer, Papillary
Downregulation of LSD1 suppresses the proliferation, tumorigenicity and invasion of papillary thyroid carcinoma K1 cells.
Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1? and microRNA-146a.
microRNA-181a promotes the oncogene S100A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C.
Tics
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability.
Tongue Neoplasms
High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer.
Triple Negative Breast Neoplasms
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Ureteral Obstruction
Lysine-specific demethylase 1 induced epithelial-mesenchymal transition and promoted renal fibrosis through Jagged-1/Notch signaling pathway.
Urinary Bladder Neoplasms
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21.
Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1?.
Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer.
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
Uterine Cervical Neoplasms
Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis.
Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer.
Uterine Neoplasms
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
Vascular System Injuries
Critical role of histone demethylase JMJD3 in the regulation of neointima formation following vascular injury.
Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats.
Virus Diseases
Correction: Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.
Histone demethylase LSD1 regulates hematopoietic stem cells homeostasis and protects from death by endotoxic shock.
Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.
Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
T Follicular Helper Cell-Dependent Clearance of a Persistent Virus Infection Requires T Cell Expression of the Histone Demethylase UTX.
[histone h3]-n6,n6-dimethyl-l-lysine4 fad-dependent demethylase deficiency
Histone Demethylase LSD1 Deficiency during High Salt Diet is Associated with Enhanced Vascular Contraction, Altered NO-cGMP Relaxation Pathway, and Hypertension.
[histone h3]-trimethyl-l-lysine4 demethylase deficiency
Effect of histone demethylase KDM5A on the odontogenic differentiation of human dental pulp cells.
[histone h3]-trimethyl-l-lysine9 demethylase deficiency
Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression.
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Jmjd1a demethylase-regulated histone modification is essential for cAMP-response element modulator-regulated gene expression and spermatogenesis.
JMJD1A Represses the Development of Cardiomyocyte Hypertrophy by Regulating the Expression of Catalase.
KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway.
Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway.
Rescuing the aberrant sex development of H3K9 demethylase Jmjd1a-deficient mice by modulating H3K9 methylation balance.